ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,554.59
0.23%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Aurinia Pharmaceuticals Inc (AUPH)

  7. Aurinia Pharmaceuticals Inc (AUPH) Noticias

AUPH Aurinia Pharmaceuticals Inc

4.9001
0.0301 (0.62%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Aurinia Pharmaceuticals Inc AUPH NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.0301 0.62% 4.9001 18:43:37
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
4.89 4.86 5.01 4.91 4.87
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
16/4/202409:48BWUPDATE: New Aurinia Presentation Details at the 2024 Bloom..
15/4/202405:00BWAurinia Pharmaceuticals to Release First Quarter Financial..
09/4/202405:00BWAurinia Will Attend 2024 Bloom Burton & Co. Healthcare..
07/3/202415:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202415:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202415:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202415:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202415:10EDGAR2Form 8-K - Current report
29/2/202407:30BWAurinia Receives Exemptive Relief from Canadian Securities..
27/2/202407:30BWAurinia to Participate in Upcoming Investor Healthcare..
22/2/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202415:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202415:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202415:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202415:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202415:19EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
15/2/202405:16EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
15/2/202405:06EDGAR2Form 8-K - Current report
15/2/202405:00BWAurinia Discloses 2023 Year-End Financial and Operational..
14/2/202414:27EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/2/202407:30BWAurinia Pharmaceuticals to Release 2023 Fourth Quarter and..
05/1/202405:02EDGAR2Form 8-K - Current report
05/1/202405:00BWAurinia Provides Preliminary Unaudited Fourth Quarter and..
20/12/202305:00BWAurinia Submits IND Application to US Food & Drug..
13/11/202305:00BWAurinia Pharmaceuticals Announces Collaboration Partner..
07/11/202309:30BWAurinia Presents Breadth of Data from AURORA Clinical..
02/11/202317:00BWAurinia Presents Breadth of Data at ASN 2023 Demonstrating..
02/11/202305:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202305:01EDGAR2Form 8-K - Current report
02/11/202305:00BWAurinia Pharmaceuticals Reports Third Quarter and Nine..
26/10/202314:00BWAurinia Response in Support of 2023 Updated EULAR..
19/10/202309:31BWCORRECTING and REPLACING Aurinia Pharmaceuticals to Release..
19/10/202305:00BWAurinia Pharmaceuticals to Release Third Quarter Financial..
13/10/202311:00BWAurinia Pharmaceuticals Announces Presentations at American..
22/9/202315:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/9/202315:06EDGAR2Form 8-K - Current report
21/9/202305:00BWAurinia Board of Directors Appoints Dr. Robert T. Foster as..
21/8/202315:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202315:11EDGAR2Form 8-K - Current report
21/8/202305:00BWAurinia Appoints Two New Board Directors with Deep..
03/8/202305:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202305:03EDGAR2Form 8-K - Current report
03/8/202305:00BWAurinia Pharmaceuticals Reports Second Quarter and Six..
20/7/202305:00BWAurinia Pharmaceuticals to Release Second Quarter Financial..
19/7/202311:05BWLong Term Phase 3 Data Published in Arthritis & Rheumatology..
06/7/202307:33EDGAR2Form PX14A6G - Notice of exempt solicitation submitted by..
03/7/202305:06EDGAR2Form 8-K - Current report
29/6/202315:05BWAurinia Board of Directors Announces Exploration of..
20/6/202308:00BWAurinia Showcases Three Oral Presentations for LUPKYNIS®..
01/6/202308:00BWLUPKYNIS® (voclosporin) Achieved Significantly Higher Renal..

Su Consulta Reciente

NASDAQ
AUPH
Aurinia Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados